Biotech Values

[DewDiligence]

India and China probably give TEVA steep competition in terms of low cost generics, legal or otherwise. Difficult to believe that an outside generic company could be cost effective there.

SNY claims to be making good money in China, which is why I take Teva’s comments about the Chinese market with a grain of salt. Notable factoid: according to Hanspeter Spek, SNY’s head of pharma, the price SNY realizes on branded Plavix is higher in China than it is in France.